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Prognostic Value of Pharmacological Stress
chocardiography in Diabetic and Nondiabetic
atients With Known or Suspected Coronary Artery Disease
auro Cortigiani, MD,* Riccardo Bigi, MD,† Rosa Sicari, MD,‡ Patrizia Landi, BSC,‡
rancesco Bovenzi, MD,* Eugenio Picano, MD‡
ucca, Milan, and Pisa, Italy
OBJECTIVES We sought to compare the prognostic value of pharmacological stress echocardiography (SE)
in diabetic and nondiabetic patients with known or suspected coronary artery disease.
BACKGROUND Although SE is a useful tool for risk stratification of patients with diabetes, it has not been
established whether it retains the same prognostic information in diabetic patients compared
with nondiabetic patients.
METHODS A total of 5,456 patients (749 diabetics) undergoing dipyridamole (n 3,306) or dobutamine
(n  2,150) SE were prospectively followed up for the occurrence of hard events (death
and/or nonfatal myocardial infarction).
RESULTS During a median time of 31 months, 411 deaths and 236 infarctions occurred. There were
132 events in diabetic patients and 515 in nondiabetic patients (18% vs. 11%, respectively;
p  0.0001). Moreover, 1,607 (29%) patients underwent coronary revascularization and were
censored. Ischemia at SE, resting wall motion score index, and age were independent
predictors of death and hard events in both diabetic and nondiabetic patients. Compared with
a normal test, ischemia and scar test patterns were associated to significantly lower
age-corrected five-year hard event-free survival in diabetic as well as nondiabetic patients.
However, a normal test was associated with a greater than two-fold annual event rate in
diabetic patients as compared with nondiabetics who were either younger (2.6% vs. 1.0%) or
older (5.5% vs. 2.2%) than 65 years of age.
CONCLUSIONS Stress echocardiography is equally effective in risk stratifying diabetic and nondiabetic patients
independently of age. However, the normal test result predicts a less favorable outcome in
diabetic than in nondiabetic patients. (J Am Coll Cardiol 2006;47:605–10) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.09.035American College of Cardiology Foundation
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doronary artery disease (CAD) is the leading cause of
ortality and morbidity in patients with diabetes. Approx-
mately one-half of deaths are attributed to CAD in diabetic
atients (1), whose risk of myocardial infarction or cardiac
eath is two- to four-fold as great compared with nondia-
etic patients (2,3). Moreover, cardiac events are as frequent
n diabetic patients without evidence of CAD as in nondi-
betic patients with known CAD (4). The increased risk
ssociated with diabetes calls for effective prevention (5–8)
nd risk stratification strategies to optimize therapeutic
nterventions (9). Exercise testing is of limited value in the
iabetic population because exercise capacity is often im-
aired by peripheral vascular (10) or neuropathic disease
11). Furthermore, test specificity is less than ideal (12)
ecause of the high prevalence of hypertension (13) and
icrovascular disease (14).
Stress echocardiography (SE) represents an established
iagnostic (15) and prognostic modality (16–19) in diabetic
atients. However, it is still undefined whether it retains the
ame prognostic value in diabetic and nondiabetic patients.
ccordingly, we aimed at comparing the ability of pharma-
From the *Division of Cardiology, Lucca Hospital, Lucca, Italy; †Cardiology,
epartment of Medicine and Surgery, University School of Medicine, Milan, Italy;
nd the ‡Institute of Clinical Physiology, CNR, Pisa, Italy.l
Manuscript received June 29, 2005; revised manuscript received September 8, 2005,
ccepted September 12, 2005.ological SE to risk stratify a large population of diabetic
nd nondiabetic patients with known or suspected CAD.
ETHODS
atients. From the prospective data bank of the Clinical
hysiology Institute, Pisa, and Campo di Marte Hospital,
ucca, Italy, 5,566 patients undergoing pharmacological
E from 1986 to 2001 were initially selected. Exclusion
riteria were significant valvular or congenital heart disease,
rognostically relevant noncardiac diseases (i.e., cancer,
nd-stage renal disease, or severe obstructive pulmonary
isease), and inadequate acoustic window. One hundred ten
2%) patients were lost to follow-up. The remaining 5,456
atients, 749 (14%) of whom were diabetics (20), had complete
ollow-up information and formed the study population. In-
ication of SE was suspected CAD in 3,268 (60%) and risk
tratification of known CAD in 2,188 (40%) subjects. Coro-
ary artery disease was defined as history of myocardial
nfarction or coronary revascularization and/or presence of
ore than one angiographically documented coronary ste-
osis 50%. Pharmachological stress was used because of
nability to exercise maximally, nondiagnostic, or doubtful
xercise electrocardiography result. The stressor (n  3,306
ipyridamole and n  2,150 dobutamine) agent was se-ected on the basis of clinical background and specific
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Stress Echocardiography in Diabetic and Nondiabetic Patients February 7, 2006:605–10ontraindications. Dobutamine was preferentially (63%)
sed in case of resting wall motion abnormalities.
Stress echocardiography was performed on and off anti-
nginal therapy in 1,409 (36%) (beta-blockers in 644,
alcium antagonists in 513, or nitrates in 916) and 4,047
74%) patients, respectively. Hypertension (5) and hyper-
holesterolemia (21) were defined according to standard
efinitions.
tress protocol. Dipyridamole and dobutamine-atropine
E was performed according to established protocols
22,23). Starting in 1992, the dipyridamole protocol was
odified to include the coadministration of atropine (24).
chocardiographic analysis. Echocardiographic images were
emiquantitatively assessed using a 16-segment, four-point
cale model of the left ventricle. A wall motion score index
WMSI) was derived by dividing the sum of individual
egment scores by the number of interpretable segments.
schemia was defined as stress-induced new and/or worsen-
Table 1. Clinical, Baseline, and Stress Echocar
Nondiabetic Patients
Diabetics (n
Clinical findings
Age (yrs) 64  9
Men 457 (61
Previous myocardial infarction 318 (42
Previous revascularization 65 (9%
Previous angioplasty 24 (3%
Previous surgery 41 (6%
Known CAD 338 (45
Hypertension 397 (53
Hypercholesterolemia 294 (39
Smoking habit 260 (35
Left bundle branch block 36 (5%
Insulin therapy 240 (32
Hypoglycemic agents 565 (75
Antianginal therapy
Beta-blockers 102 (14
Calcium antagonists 109 (15
Nitrates 176 (23
Resting echocardiogram
WMA 429 (57
WMSI 1.29  0
Stress echocardiography
Dipyridamole 544 (73
Dobutamine 205 (27
Ischemic result 308 (41
Scar 229 (31
Peak WMSI 1.40  0
ECG changes during test 211 (28
Angina during test 161 (21
Data presented are mean value  SD or number (%) of pat
Abbreviations and Acronyms
CAD  coronary artery disease
SE  stress echocardiography
WMSI  wall motion score indexCAD  coronary artery disease; ECG  electrocardiographic; W
score index.ng of pre-existing wall motion abnormality, or biphasic
esponse (i.e., low-dose improvement followed by high-dose
eterioration). Scar was akinetic or dyskinetic myocardium,
ith no thickening during stress. A test was normal in case
f no rest and stress wall motion abnormality. Electrocar-
iographic analysis was done according to standard criteria
22,23).
ollow-up. Data collection was performed in 2002. Out-
ome was determined from patients’ interviews at the
utpatient clinic, hospital chart reviews, and telephone
nterviews with the patient, his/her close relative, or refer-
ing physician. Death, nonfatal myocardial infarction, and
oronary revascularization were registered as clinical events.
o avoid misclassification of the cause of death (25), we
onsidered overall mortality. Myocardial infarction was defined
y typical symptoms, electrocardiographic, and cardiac enzyme
hanges. Follow-up data were analyzed for the prediction of
eath and hard events (death, myocardial infarction).
tatistical analysis. Continuous variables are expressed as
ean values  SD. Differences between groups were
ompared using the Student t and chi-square tests, as
ppropriate. Survival rates were estimated with Kaplan-
eier curves and compared by the log-rank test. Patients
ndergoing coronary revascularization were censored at the
raphy Characteristics for Diabetic and
9) Nondiabetics (n  4,707) p Value
61  11 0.0001
2,942 (62%) 0.43
1,730 (37%) 0.003
311 (7%) 0.04
159 (3%) 0.81
152 (3%) 0.002
1,850 (39%) 0.003
1,891 (40%) 0.0001
1,716 (36%) 0.14
2,110 (45%) 0.0001
191 (4%) 0.34
0 0.0001
0 0.0001
542 (12%) 0.10
404 (9%) 0.0001
740 (16%) 0.0001
2,168 (46%) 0.0001
1.22  0.32 0.0001
2,762 (59%) 0.0001
1,945 (41%) 0.0001
1,732 (37%) 0.02
1,132 (24%) 0.0001
1.31  0.36 0.0001
1,268 (27%) 0.48
1,171 (25%) 0.04diog
 74
%)
%)
)
)
)
%)
%)
%)
%)
)
%)
%)
%)
%)
%)
%)
.35
%)
%)
%)
%)
.37
%)
%)
ients.
MA  wall motion abnormalities; WMSI  wall motion
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February 7, 2006:605–10 Stress Echocardiography in Diabetic and Nondiabetic Patientsime of the procedure. Only the first event was taken into
ccount. Annual event rates were obtained from Kaplan-
eier estimates to take censoring of the data into account.
he association of selected variables with outcome was
ssessed with the Cox’s proportional hazards survival model
sing univariate and stepwise multivariate procedures. A
ignificance of 0.05 was required for a variable to be
ncluded into the multivariate model, whereas 0.1 was the
ut-off value for exclusion. Hazard ratios with the corre-
ponding 95% confidence intervals were estimated. The
odel was stratified by age according to the cut-off of 65
ears. Statistical significance was set at p  0.05. Moreover,
linical, rest, and stress-induced wall motion abnormalities
equentially were included into the model. The global
hi-square value of the model was calculated from the log
ikelihood ratio; a significant increase after the addition of
urther variables indicated incremental prognostic value.
tatistical Package for the Social Sciences (SPSS, Chicago,
llinois) was used for analysis.
ESULTS
tress echocardiography. Ischemia was assessed in 2,040
37%) patients (1,232 [61%] with resting wall motion
bnormalities), 308 of whom were diabetic and 1,732
ondiabetic (41% vs. 37%, p  0.02). Ischemia was more
requent in patients with than in those without resting wall
otion abnormalities (48% vs. 28%; p  0.0001). Among
ubjects with ischemia, the WMSI increased from 1.28 
.31 to 1.56  0.33 in diabetic patients and from 1.27 
.31 to 1.54  0.33 in nondiabetic patients (p  0.37)
uring stress. The number of ischemic segments was similar
n the two populations (2.54  1.51 vs. 2.58  1.50, p 
.81).
A scar pattern was found in 229 diabetic and 1,132
ondiabetic patients (31% vs. 24%; p  0.0001); diabetic
atients had a greater WMSI (1.56  0.33 vs. 1.49  0.34;
able 2. Univariate and Multivariate Predictors of Mortality in D
Diabetics
Univariate Analysis Multivaria
HR (95% CI) p Value HR (95% C
ge (yrs) 1.06 (1.03–1.09) 0.0001 1.06 (1.03–1.
ender (male) 1.06 (0.68–1.66) 0.80
revious infarction 1.47 (0.95–2.26) 0.08
revious revascularization 1.16 (0.53–2.52) 0.71
nown CAD 1.43 (0.93–2.20) 0.11
ypertension 0.92 (0.60–1.42) 0.71
ypercholesterolemia 0.94 (0.60–1.47) 0.77
moking habit 1.07 (0.68–1.68) 0.76
eft bundle branch block 1.55 (0.67–3.57) 0.30
esting WMA 2.34 (1.44–3.81) 0.001
esting WMSI 4.04 (2.42–7.65) 0.0001 3.20 (1.88–5.
schemia at stress echo 1.69 (1.09–2.61) 0.02 1.79 (1.15–2.
eak WMSI 3.62 (2.15–6.08) 0.0001
CG changes during test 0.78 (0.46–1.33) 0.36
ngina during test 0.89 (0.51–1.56) 0.68AD  coronary artery disease; CI  confidence interval; ECG  electrocardiographic; HR  0.004). A normal test was observed in 212 diabetic and
,843 nondiabetic patients (28% vs. 39%; p  0.0001).
linical and echocardiographic characteristics of the study
opulation are reported in Table 1.
ollow-up events. The follow-up period ranged from 6 to
20 months (median, 31; first quartile 6, third quartile 65
onths). A total of 647 hard events (411 deaths, 236
yocardial infarctions) were observed: 132 in diabetic and
15 in nondiabetic patients (18% vs. 11%; p  0.0001).
ccording to age, 58 events occurred in the 368 diabetic and
61 in the 2,938 nondiabetic patients younger than 65 years
16% vs. 9%; p 0.0001), whereas 74 events occurred in the
81 diabetic and 254 in the 1,769 nondiabetic patients older
han 65 years (19% vs. 14%; p  0.0001). Among diabetic
atients, 106 events occurred in the 537 patients with
bnormal and 26 in the 212 with normal test (20% vs. 12%;
 0.01). Among nondiabetic patients, 398 events oc-
urred in the 2,864 patients with abnormal and 117 in the
,843 with normal test (14% vs. 6%; p  0.0001). In
atients with scar, a higher WMSI was documented in both
iabetic patients (1.65  0.35 vs. 1.53  0.31; p  0.01),
nd nondiabetics (1.54  0.37 vs. 1.48  0.34; p  0.03)
ith events as compared with their uneventful counterpart.
A total of 1,607 (29%) patients (263 [35%] diabetic and
,344 [28%] nondiabetic patients; p  0.0002) underwent
oronary revascularization (675 surgery and 932 angio-
lasty): 743 (46%) within and 864 (54%) after three months
rom SE.
utcome prediction. The annual hard event rate was
igher in diabetic than in nondiabetic patients either with
8.5% vs. 4.7%) or without (6.0% vs. 2.2%) known CAD.
f note, it was higher in diabetic patients without known
AD than in nondiabetic patients with known CAD.
Univariate and multivariate predictors of mortality in
iabetic and nondiabetic patients are reported in Table 2.
schemia at SE, resting WMSI, and age were independently
tic and Nondiabetic Patients
Nondiabetics
nalysis Univariate Analysis Multivariate Analysis
p Value HR (95% CI) p Value HR (95% CI) p Value
0.0001 1.07 (1.06–1.08) 0.0001 1.06 (1.05–1.08) 0.0001
1.78 (1.38–2.28) 0.0001 1.52 (1.18–1.96) 0.001
2.21 (1.78–2.75) 0.0001
0.99 (0.62–1.60) 0.98
2.14 (1.72–2.66) 0.0001
1.17 (0.94–1.47) 0.16
1.07 (0.84–1.35) 0.58
1.11 (0.89–1.38) 0.36
1.55 (0.96–2.50) 0.07
2.77 (2.21–3.47) 0.0001
0.0001 5.15 (4.01–6.60) 0.0001 3.64 (2.80–4.73) 0.0001
0.01 2.09 (1.68–2.61) 0.0001 1.76 (1.41–2.19) 0.0001
5.56 (4.38–7.06) 0.0001
1.12 (0.88–1.44) 0.35
1.08 (0.84–1.39) 0.53iabe
te A
I)
08)
46)
79)hazard ratio; WMA  wall motion abnormalities; WMSI  wall motion score index.
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Stress Echocardiography in Diabetic and Nondiabetic Patients February 7, 2006:605–10ssociated with mortality in both groups. In nondiabetic
atients, male gender also was a multivariate prognostic
ndicator. Compared with a normal test, ischemia and scar
atterns predicted a significantly lower five-year survival in
oth diabetic (p  0.001) and nondiabetic patients (p 
.0001) (Fig. 1).
Ischemia at SE, resting WMSI, and age also were
ultivariate prognostic indicators of hard events (Table 3)
n both patient groups. Furthermore, previous myocardial
nfarction, smoking habit, and left bundle branch block
epresented additional prognostic indicators in nondiabet-
cs. Compared with a normal test, ischemia and scarring
ere associated with significantly lower five-year hard
vent-free survival in both diabetic (p  0.0001) and
ondiabetic patients (p  0.0001; Fig. 2).
The results of SE retained their prognostic value after
rouping patients by age (Fig. 3). However, a normal test
as associated with worse outcome in diabetic than in
ondiabetic patients, particularly if they were older than 65
ears (Fig. 3). Annual hard event rate associated with a
ormal test was approximately 2.5 times greater in diabetic
atients than in nondiabetic patients who were both
Figure 1. Survival curves for diabetic and nondiabetic pati
able 3. Univariate and Multivariate Predictors of Hard Events i
Diabetics
Univariate Analysis Multivaria
HR (95% CI) p Value HR (95% C
ge (yrs) 1.03 (1.01–1.05) 0.001 1.03 (1.01–1.
ender (male) 1.10 (0.77–1.58) 0.58
revious infarction 1.47 (1.04–2.08) 0.03
revious revascularization 1.33 (0.73–2.41) 0.35
nown CAD 1.45 (1.03–2.04) 0.03
ypertension 0.96 (0.69–1.35) 0.80
ypercholesterolemia 0.92 (0.64–1.32) 0.65
moking habit 1.06 (0.74–1.52) 0.73
eft bundle branch block 1.46 (0.71–3.00) 0.30
esting WMA 2.57 (1.66–3.97) 0.0001
esting WMSI 3.17 (2.07–4.86) 0.0001 2.73 (1.75–4.
schemia at stress echo 1.65 (1.16–2.34) 0.005 1.65 (1.16–2.
eak WMSI 2.86 (1.88–4.36) 0.0001
CG changes during test 0.95 (0.64–1.42) 0.80
ngina during test 1.04 (0.68–1.59) 0.86AD  coronary artery disease; CI  confidence interval; ECG  electrocardiographic; HR ounger (2.6% vs. 1.0%) and older (5.5% vs. 2.2%) than 65
ears. Six-month hard event rate was 0.9% in diabetics
ounger and 3% in those older than 65 years.
Global chi-square of the clinical model for predicting
utcome was 17.8 (p  0.02) in diabetic and 209.5 (p 
.0001) in nondiabetic patients. Sequential inclusion of
esting and SE result increased it by 31% (23.4; p  0.005)
nd 28% (29.9; p  0.001) in diabetic and by 11% (232.0;
 0.0001) and 16% (269.9; p  0.0001) in nondiabetic
atients, respectively.
Dipyridamole and dobutamine SE provided a similar
ncrement in global chi-square in both diabetic (20% and
1%, respectively) and nondiabetic patients (16% and 17%,
espectively). Annual hard event rate associated with a
onischemic test was greater in both diabetic (7.8% vs.
.3%) and nondiabetic patients (3.8% vs. 2.1%) if the test
as performed on rather than off antianginal therapy.
ISCUSSION
he prognostic value of SE in diabetic patients with known
r suspected CAD has been previously demonstrated (16–19).
escribing the group with ischemia, scar, and normal test.
abetic and Nondiabetic Patients
Nondiabetics
nalysis Univariate Analysis Multivariate Analysis
p Value HR (95% CI) p Value HR (95% CI) p Value
0.004 1.05 (1.04–1.06) 0.0001 1.04 (1.03–1.05) 0.0001
1.51 (1.24–1.83) 0.0001
2.25 (1.89–2.67) 0.0001 1.48 (1.21–1.81) 0.0001
1.14 (0.81–1.62) 0.45
2.17 (1.82–2.58) 0.0001
1.23 (1.03–1.47) 0.02
1.10 (0.92–1.33) 0.30
1.24 (1.04–1.47) 0.02 1.27 (1.05–1.53) 0.02
1.62 (1.10–2.37) 0.01 1.91 (1.29–2.83) 0.001
2.45 (2.05–2.92) 0.0001
0.0001 3.62 (2.94–4.47) 0.0001 2.27 (1.77–2.91) 0.0001
0.005 2.10 (1.76–2.49) 0.0001 1.74 (1.45–2.08) 0.0001
4.06 (3.33–4.95) 0.0001
1.25 (1.03–1.52) 0.03
1.13 (0.93–1.38) 0.23n Di
te A
I)
05)
25)
35)hazard ratio; WMA  wall motion abnormalities; WMSI  wall motion score index.
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February 7, 2006:605–10 Stress Echocardiography in Diabetic and Nondiabetic Patientsowever, given their high-risk status for the development
f cardiovascular diseases (1–4), diabetic patients present
ith a substantially increased pretest likelihood of adverse
utcome. Thus, to verify whether the test conveys similar
rognostic information in diabetic and nondiabetic patients
s of primary clinical relevance. With this aim in mind, we
nalyzed the data of a large cohort of patients with and
ithout diabetes mellitus who were referred for pharma-
ological SE. Diabetic patients had a higher risk profile,
s demonstrated in the more advanced age and higher
revalence of CAD, hypertension, resting wall motion
bnormalities, and ischemic or scar echocardiographic
attern. Moreover, they more frequently underwent coro-
ary interventions and fared worse than nondiabetic pa-
ients independently of the presence of a known CAD.
iabetic patients with suspected CAD had a worse prog-
Figure 2. Hard event-free survival curves for diabetic and nondiabigure 3. Hard event-free survival curves for diabetic and nondiabetic patients
nd normal test.osis in comparison with nondiabetic patients with known
AD.
Despite these differences, clinical and echocardiographic
ndings allowed the effective risk stratification in both
atient populations. In particular, age, ischemia at SE, and
esting WMSI were independent predictors of outcome.
nterestingly, SE added greater prognostic value to that of
linical and resting echo findings in diabetic than in non-
iabetic patients independently of the stressor agent. More-
ver, using the test result, we were able to separate subsets
ith different risk profiles in both groups of patients indepen-
ently of age, even though a normal test was associated with a
orse outcome in diabetic patients as compared with age-
atched nondiabetic patients. Similar results were reported
reviously (26); however, as the scar pattern was included
mong the nonischemic results, the authors did not sepa-
atients describing the group with ischemia, scar, and normal test.ages 65 years and 65 years, describing the group with ischemia, scar,
r
t
p
a
(
C
p
d
p
S
a
w
p
F
“
t
m
t
(
m
o
S
l
o
m
d
t
h
t
R
D
I
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
610 Cortigiani et al. JACC Vol. 47, No. 3, 2006
Stress Echocardiography in Diabetic and Nondiabetic Patients February 7, 2006:605–10ately analyze the prognostic effect of a normal test. Short-
erm prognostic significance of a normal SE in diabetic
atients was less favorable in the present as compared with
previous study reporting no event during the first two years
17).
linical implications. Our results reinforce previous re-
orts on the capability of SE to effectively stratify the risk of
eath (18) or combined hard events (16,17,19) in diabetic
atients. However, further conclusions may be drawn. First,
E provides useful prognostic information in diabetics younger
s well as older than 65 years. Moreover, diabetic patients
ith a normal test have a less favorable outcome as com-
ared with their age-matched nondiabetic counterpart.
inally, a normal study is associated with a measurable
warranty period” in diabetics younger but not in those older
han 65 years. On the basis of these findings, the achieve-
ent of as much metabolic control as possible, adequate
reatment of risk factors (8), primary prevention measures
6,7), as well as close follow-up, including periodic assess-
ent of myocardial ischemia, should represent pivotal targets
f the management of diabetic patients with normal SE.
tudy limitations. Because patients were recruited over a
ong period of time, it is possible that progressive method-
logical and technological advancements in SE as well as in
edical therapy may have affected our results. Moreover,
obutamine stress was preferentially administered to pa-
ients with resting wall motion abnormalities which may
ave caused a misinterpretation of the relationship between
ype of stressor and outcome.
eprint requests and correspondence: Dr. Lauro Cortigiani,
ivisione di Cardiologia, Ospedale “Campo di Marte,” 55032 Lucca,
taly. E-mail: lacortig@tin.it.
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